ClinicalTrials.gg
RecruitingNCT07946861Updated Nov 18, 2026

Intramedullary Nailing for Femoral Shaft Fractures

An interventional study of Femoral Intramedullary Nail and OrthoXel Micromotion Nailing System in Femoral Shaft Fracture, sponsored by Indiana University. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Indiana University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Sep 2026; still recruiting 2 months later.
Updated Nov 18, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
290
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

A randomized controlled trial that is trying to find the best treatment for a severe upper leg (i.e., thigh, also known as femoral shaft) fracture. One type of treatment, which is called micromotion intramedullary (within the hollow center of the bone) nailing, is a type of nail used for thigh fracture treatments that helps to heal the bone by allowing a small amount of controlled movement. Another type, called non-micromotion intramedullary nailing, is also used to treat thigh fractures but does not include this controlled-movement feature. Both treatments are approved by the FDA but have not been directly compared to each other. Participation includes being assigned to receive either a micromotion intramedullary nail or a non-micromotion intramedullary nail. Those that participate will be randomly assigned (like a flip of a coin) to one of those treatment methods and return for standard follow-up visits. In addition to those regular clinical follow-ups, participants will complete some brief surveys/questionnaires while they are in the hospital. Research staff will also look at past medical history.

02

Conditions studied

  • Femoral Shaft Fracture
03

In context

Lead sponsor

Indiana University is the lead sponsor of 990 studies on the registry; 201 are open to participants now.

Of its 150 completed or terminated interventional studies of FDA-regulated products, 118 (79%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients aged 18-84 years old inclusive with a femoral shaft fracture deemed appropriate for treatment with an IMN by the treating surgeon

Exclusion criteria

Exclusion Criteria:

  • Not within age range
  • Planned treatment with dominant implants other than IMN
  • Non-ambulatory at baseline
  • Fracture needs a planned-staged secondary procedure for bone defects (e.g., Masquelet)
  • Any previous surgery on the index site
  • Fracture fixation >28 days from injury
  • Fractures that the treating surgeon indicates require any additional fixation that spans the fracture. These patients will be late ineligible
  • Patients with a history of infection or a current active infection at the surgical site
  • Patients undergoing revision surgery following primary fixation
  • Patients undergoing femoral nailing for a pathological fracture
  • Patients undergoing bone transport over an intramedullary nail
  • Non-English or Non-Spanish speaking
  • Prisoners or impending incarceration
  • Patients unwilling or unable to participate in study protocol or follow up in the IU system for 12 months
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
290 participants (estimated)

Study arms

  • Active comparator
    Standard Intramedullary Nailing

    Device: Femoral Intramedullary Nail

  • Experimental
    OrthoXel Micromotion Intramedullary Nail

    Device: OrthoXel Micromotion Nailing System

Interventions

  • DeviceFemoral Intramedullary Nail

    A rod inserted into the hollow center of a long bone to hold a broken bone in place while it heals.

  • DeviceOrthoXel Micromotion Nailing System

    An intramedullary nail that allows for controlled axial micromotion.

06

What researchers measure

Primary outcomes

  1. Superiority of micromotion nailing over non-micromotion IMN according to a composite outcome using a win ratio reflective of improved femoral shaft fracture healing

    Time frame: From enrollment to end of treatment at about a year.

Secondary outcomes

  1. Iindividual levels of the win-ratio pyramid between the micromotion nailing and non-micromotion nailing groups.

    Time frame: From enrollment to end of treatment at about a year.

  2. Superiority of micromotion nailing in a subgroup of patients at high baseline risk for nonunion.

    Time frame: From enrollment to end of treatment at about a year.

  3. Number of patients with Adverse Events and Complications between the Micromotion nail and standard of care intramedullary nails.

    Time frame: From enrollment to end of treatment at about a year.

  4. Change in daily step count from pre-injury baseline between the micromotion nailing and non-micromotion nailing groups.

    Daily step count, measured in steps per day, will be obtained from the Apple Health app on the participant's iPhone. Participants will download the OrthoSteps app once to transfer their Apple Health data to the study team. Step counts will be assessed at the pre-injury baseline and at each post-injury follow-up.

    Time frame: From enrollment to end of treatment at about a year.

  5. Gait balance between the two groups as calculated by the GaitMap.

    Time frame: From enrollment to end of treatment at about a year

  6. Walking speed using a GaitMap

    Time frame: From enrollment to end of treatment at about a year.

  7. Modified Radiographic union scores for femoral shaft fractures

    Time frame: From enrollment to end of treatment at about a year.

07

Study locations

1 of 1 sites recruiting
  • Indiana University Health Methodist Hospital
    Indianapolis, Indiana 46202, United States
    Recruiting
    • Cora F Mizimakoski, Bachelor of Science · Contactcmizimak@iu.edu · 317-963-5034
    • Roman Natoli, MD, PhD · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2026 (actual). Primary completion is estimated for Sep 2031, 60 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 26, 2026
First posted
Nov 18, 2026
StartActual
Sep 15, 2026
Primary completionEst.
Sep 2031
CompletionEst.
Sep 2031
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07946861
Lead sponsor
Indiana University
Collaborators
OrthoXel
Responsible party
Roman M. Natoli (Associate Professor, Department of Orthopaedic Surgery, Clinical Associate Director, Indiana Center for Musculoskeletal Health, Indiana University) — Principal investigator
First posted
Nov 18, 2026
Start date
Sep 15, 2026
Primary completion
Sep 2031 (estimated)
Completion
Sep 2031 (estimated)
Last update
Nov 18, 2026

Study contacts

Roman Natoli, MD, PhD
principal investigator · Indiana University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion